The relationship of serum hemojuvelin and hepcidin levels with iron overload in nonalcoholic fatty liver disease

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 3, 2015, Pages 293-300

  Boga, Salih ^a   Alkim, Huseyin ^a   Alkim, Canan ^a   Koksal, Ali Riza ^a   Bayram, Mehmet ^a   Ozguven, Muveddet Banu Yilmaz ^b   Neijmann, Sebnem Tekin ^c  

^a Department of Gastroenterology ^*  (Turkey)

^b II Ear Nose Throat Head and Neck Surgery   (Turkey)

^c BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Hemojuvelin; Hepcidin; Iron; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOJUVELIN; HEPCIDIN; LIPOPROTEIN; TRANSFERRIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HAMP PROTEIN, HUMAN; HFE2 PROTEIN, HUMAN;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; FIBROSIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; IRON METABOLISM; IRON OVERLOAD; LIVER BIOPSY; LIVER HEMOSIDEROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STEATOSIS; BIOPSY; BLOOD; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX;

ADULT; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITINS; GPI-LINKED PROTEINS; HEPCIDINS; HUMANS; INSULIN RESISTANCE; IRON OVERLOAD; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84941075430     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.243.hak     Document Type: Article

References (31)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285. doi: 10.1111/j.1365-2036.2011.04724.x
2. Mendler MH, Turlin B, Moirand R, et al. Insulin-resistance associated hepatic iron overload. Gastroenterology 1999; 117: 1155-1163. doi: 10.1016/S0016-5085(99)70401-4
3. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liasons. J Hepatol 2007; 46: 549-552. doi: 10.1016/j.jhep.2007.01.004
4. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093. doi: 10.1126/science.1104742
5. Delaby C, Pilard N, Goncalves AS, Beaumont C, CanonneHergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and downregulated by hepcidin. Blood 2005; 106: 3979-3984. doi: 10.1182/ blood-2005-06-2398
6. Aigner E, Theurl I, Theurl M, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008; 87: 1374-1383.
7. Barisani D, Pelucchi S, Mariani R, et al. Hepcidin and iron-related gene expression in subjects with dysmetabolic hepatic iron overload. J Hepatol 2008; 49: 123-133. doi: 10.1016/j.jhep.2008.03.011
8. Vuppalanchi R, Troutt JS, Konrad RJ, et al. Serum hepcidin levels are associated with obesity but not liver disease. Obesity 2014; 22: 836-841. doi: 10.1002/oby.20403
9. Demircioglu F, Gorunmez G, Dagistan E, et al. Serum hepcidin levels and iron metabolism in obese children with and without fatty liver: case-control study. Eur J Pediatr 2014; 173: 947-951. doi: 10.1007/ s00431-014-2268-8
10. Lin L, Nemeth E, Goodnough JB, Thapa DR, Gabayan V, Ganz T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis 2008; 40: 122-131. doi: 10.1016/j.bcmd.2007.06.023
11. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008; 111: 924-931. doi: 10.1182/blood-2007-07-100677
12. Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol 2005; 100: 1185-1194. doi: 10.1111/j.1572-0241.2005.40998.x
13. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007; 110: 2182-2189. doi: 10.1182/blood-2007-04-087593
14. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. doi: 10.1002/hep.20701
15. Searle J LB, Crawford DH, Powell LW. Iron storage disease. In: MacSween RNM, Burt AD, Portman BC, et al. (eds.). Pathology of the liver. 4th ed. New York, NY: Churchill Livingstone, 2002.
16. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and itsmutation leads to severe iron overload. J Clin Invest 2005; 115: 2180-2186. doi: 10.1172/JCI25683
17. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82. doi: 10.1038/ng1274
18. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810. doi: 10.1074/jbc.M008922200
19. Fujita N, Sugimoto R, Motonishi S, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 2008; 49: 702-710. doi: 10.1016/j.jhep.2008.05.014
20. Haap M, Fritsche A, Mensing HJ, Häring HU, Stumvoll M. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med 2003; 139: 869-871. doi: 10.7326/0003-4819-139-10-200311180-00027
21. Elsammak M, Refai W, Elsawafi A, Abdel-Fattah I, Abd Elatti E, Ghazal A. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 2005; 21: 527-534. doi: 10.1185/030079905X38141
22. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C: metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Res Clin Pract 2007; 75: 320-326. doi: 10.1016/j.diabres.2006.07.008
23. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-744. doi: 10.1053/jhep.2001.28055
24. George DK, Goldwurm S, Macdonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318. doi: 10.1016/ S0016-5085(98)70482-2
25. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-429. doi: 10.1016/S0168-8278(99)80032-4
26. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-850. doi: 10.1002/hep.510300407
27. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors ofliver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356 -1362. doi: 10.1002/hep.510300604
28. Bugianesi E, Manzini P, D’Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-187. doi: 10.1002/ hep.20023
29. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-149. doi: 10.1053/ jhep.2002.33892
30. Barut G, Balci H, Bozdayi M, Hatemi I, Ozcelik D, Senturk H. Screening for iron overload in the Turkish population. Dig Dis 2003; 21: 279-285. doi: 10.1159/000073985
31. Bozkaya H, Bektas M, Metin O, et al. Screeni ng f or hemochromatosis in Turkey. Dig Dis Sci 2004; 49: 444-449. doi: 10.1023/B:DDAS.0000020500.26184.ce